Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 25;7(7):e1176. doi: 10.1038/tp.2017.152

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Fatty acid (FA) elongation pathways differ between schizophrenia patients (SCZ) and healthy controls (HC). The FA elongation pathways of SFAs, MUFAs, n-3 PUFAs and n-6 PUFAs are illustrated. The histograms present the relative concentration of each free fatty acid (FFA) in HC (left) and SCZ (right, normalized by HC). Red histograms indicate increases in SCZ, whereas blue indicates decreases. The figure above the histogram is the fold change (FC), and asterisks indicate significance. The red arrows indicate a significant increase in the ratio of product: substrate, which was deduced to be enhanced in this direction. The blue arrows are the opposite and indicate ratios that were deduced to be weakened. The gray arrows indicate no statistical significance. a) The FA elongation pathways of SFAs and MUFAs. b) The FA elongation pathways of ω-6 PUFAs. c) The FA elongation pathways of ω-3 PUFAs.